Pune, India, July 13, 2022 (GLOBE NEWSWIRE) -- The global nuclear medicine market size was USD 5.04 billion in 2020. The market is projected to grow from USD 5.57 billion in 2021 to USD 19.47 billion by 2028 at a CAGR of 19.6% during the 2021-2028 period. This information is provided by Fortune Business Insights™, in its report, titled, “Nuclear Medicine Market, 2021-2028.”
According to our researchers, the market growth is primarily accredited to the rising occurrence of chronic conditions. Furthermore, technological progressions empowering the usage of radiopharmaceuticals to analyze and treat cancerous tumors aid towards market growth.
Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/nuclear-medicine-radiopharmaceuticals-market-101812
Industry Development
March 2021: Bracco Diagnostics Inc. declared a collaboration with CardioNavix, LLC to enhance patient access to cardiac PET imaging. This novel program, the Bracco Mobile Isotope Service, will empower more patient care sites to provide cardiac PET imaging.
Report Scope
| Report Coverage | Details |
| Forecast Period | 2021 to 2028 |
| Forecast Period 2021 to 2028 CAGR | 19.6% |
| 2028 Value Projection | USD 19.47 Billion |
| Base Year | 2020 |
| Market Size in 2021 | USD 5.57 Billion |
| Historical Data for | 2017 to 2019 |
| No. of Pages | 169 |
Regional Insights
North America to Lead Backed by Increased Usage of Therapeutic Radiopharmaceuticals
North America created a revenue of USD 2.57 billion in 2020 and is projected to continue its dominance during the forecast period. The prompt adoption of operative nuclear imaging technologies pooled with the rising utilization of technologically sound and proficient therapeutic radiopharmaceuticals across the region are anticipated to fuel Nuclear Medicine market growth.
Europe is estimated to hold the second-highest nuclear medicine market America share due to the adoption of advanced radiopharmaceuticals and current product unveilings by prominent players.
Asia Pacific is projected to expand at a substantial CAGR during the forecast period.
To get to know more about the short-term and long-term impact of COVID-19 on this market, please visit: https://www.fortunebusinessinsights.com/industry-reports/nuclear-medicine-radiopharmaceuticals-market-101812
Report Coverage
Our reports are conducted with an exhaustive examination method that primarily focuses on delivering accurate material. Our scholars have applied a data navigation technique that further aids us to offer reliable predictions and examine the nuclear medicine market America dynamics precisely. Further, our analysts have gained admission to various international as well as locally sponsored registers for providing the up-to-date material so that the stakeholders and business professionals invest only in operative zones.
Driving Factors
Technological Progressions in Nuclear Imaging Modalities to Boost Market
One of the fundamental aspects for the nuclear medicine market growth is the augmented consciousness concerning the possible influence of primary and timely diagnosis and the corresponding affirmative sway in the management and treatment of prolonged disorders. Developments in nuclear imaging technology, especially PET/PET-CT, have helped in the extension of applications of this modality beyond oncology to cardiology, neurology, and identification of infections.
Segmentation
On the basis of the type, the Nuclear Medicine market is categorized into diagnostic and therapeutic radiopharmaceuticals. The diagnostic radiopharmaceuticals segment is estimated to hold the dominant share of the global market in 2020.
In terms of application, the market America is classified into neurology, cardiology, oncology, and others.
By the end-user, the market is divided into hospitals & clinics, diagnostic centers, and others.
Geographically, the market is branched into North America, Europe, Asia Pacific, and the Rest of the World.
Segments-
| Segmentation | By Type
|
| By Application
| |
| By Geography
|
Quick Buy - Nuclear Medicine Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/101812
Competitive Landscape
Partnerships Commenced by Key Companies to Promote Market Growth
The dominating players in the market continually root for resourceful strategies to encourage their brand value and also promote the global market growth of the product with facing least imaginable obstacles. One such capable strategy is gaining competitive companies and therefore fortifying a profit for both the involved companies.
COVID-19 Impact
COVID-19 Pandemic Hindered Market Revenue Owing to Decreasing Diagnosis Processes
The COVID-19 pandemic adversely influenced the market in 2020. The concerns such as scarcity of workforce & staff, the threat of transmission of COVID-19, and the deterioration in the imaging processes such as PET-CT SPECT procedures posed a test for the market growth in 2020. The decline in the procedures can be accredited to the interruption in supply chains, logistical challenges, and adoption of safety measures, which is difficult to maintain by centers.
Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/nuclear-medicine-radiopharmaceuticals-market-101812
List of Key Players Covered in the Report
- Lantheus Medical Imaging, Inc. (U.S.)
- Cardinal Health (U.S.)
- Norgine B.V. (Netherlands)
- Nordion (Canada) Inc. (Canada)
- Bayer AG (Germany)
- Curium (France)
- Advanced Accelerator Applications (Novartis AG) (France)
- Bracco Diagnostic Inc. (U.S.)
- Jubilant Pharmova Limited (India)
- GE Healthcare (General Electric Company) (U.S.)
Some major points from Table of Content:
- Introduction
- Market Scope
- Market Segmentation
- Research Methodology
- Definitions and Assumptions
- Executive Summary
- Market Dynamics
- Market Drivers
- Market Restraints
- Market Opportunities
- Market Trends
- Key Insights
- Installed Base of PET/PET-CT Scanners – For Key Countries, 2015 and 2019
- Installed Base of Gamma Cameras – For Key Countries, 2019
- PET/PET-CT Procedure Volume –for Key Countries, 2019
- Reimbursement Scenario- For Key Countries
- New Product Launches
- Key Industry Developments
- Pipeline Analysis
- Impact of COVID-19 on the Market
- Global Nuclear Medicine Market Analysis, Insights and Forecast, 2017-2028
- Key Findings / Summary
- Market Analysis, Insights and Forecast – By Type
- Diagnostics
- PET Radiopharmaceuticals
- FDG-PET/18F
- 68Ga
- 68Cu
- 11C
- Others
- SPECT Radiopharmaceuticals
- Technetium-99m
- Iodine-123
- Xenon-133
- Thallium-201
- Others
- PET Radiopharmaceuticals
- Therapeutics
- Diagnostics
- Market Analysis, Insights and Forecast – By Application
- Neurology
- Cardiology
- Oncology
- Others
- Market Analysis, Insights and Forecast – By End-user
- Hospitals & Clinics
- Diagnostic Centers
- Others
- Market Analysis, Insights and Forecast – By Region
- North America
- Europe
- Asia Pacific
- Rest of the World
- North America Nuclear Medicine Market Analysis, Insights and Forecast, 2017-2028
- Key Findings / Summary
- Market Analysis, Insights and Forecast – By Type
- Diagnostics
- PET Radiopharmaceuticals
- FDG-PET/18F
- 68Ga
- 68Cu
- 11C
- Others
- SPECT Radiopharmaceuticals
- Technetium-99m
- Iodine-123
- Xenon-133
- Thallium-201
- Others
- PET Radiopharmaceuticals
- Diagnostics
Toc Continued...
Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/nuclear-medicine-radiopharmaceuticals-market-101812
About Us:
Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Contact Us:
Fortune Business Insights™ Pvt. Ltd.
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com
Press Release: https://www.fortunebusinessinsights.com/press-release/nuclear-medicine-radiopharmaceuticals-market-9463
